

# Proto oncogene protein c-myc inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/P1970AC8B816EN.html>

Date: January 2022

Pages: 96

Price: US\$ 1,500.00 (Single User License)

ID: P1970AC8B816EN

## Abstracts

This report can be delivered to the clients within 3-4 Business Days

DelveInsight's, "Proto oncogene protein c-myc inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Proto oncogene protein c-myc inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Proto oncogene protein c-myc inhibitors Understanding

#### Proto oncogene protein c-myc inhibitors: Overview

cMyc is a 62 kDa protein (439 amino acids) and belongs to the basic helix-loop-helix zipper (bHLHZip) class of transcription factors. cMyc has been implicated in multiple cellular processes, including proliferation, differentiation, apoptosis and metabolism. The four-helix structure of cMyc and MAX binds to DNA sequences, such as E-box motifs (5'-CACGTG -3'), to control transcription of specific genes. These genes have been reported to be involved in chromatin modification, DNA replication, and ribosome and mitochondrial biogenesis. A large number of proofs of principle experiments suggest that targeting cMyc may have considerable therapeutic benefit in human

tumors. cMyc binds to the MAX protein and forms dimers, which are necessary for the biological activation of cMyc. Strategies have emerged to inhibit cMyc expression, to interrupt cMyc-Max dimerization, to inhibit cMyc-Max DNA binding, to interfere with key cMyc target genes, and to inhibit cMyc in cancer stem cells (CSCs).

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene protein c-myc inhibitors R&D. The therapies under development are focused on novel approaches for Proto oncogene protein c-myc inhibitors.

## Proto oncogene protein c-myc inhibitors Emerging Drugs Chapters

This segment of the Proto oncogene protein c-myc inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Proto oncogene protein c-myc inhibitors Emerging Drugs

### RRx-001: EpicentRx Inc.

RRx-001 is a next generation, small molecule anticancer immunotherapeutic that downregulates the CD47/SIRP $\alpha$  axis and repolarizes TAMs and other immunosuppressive cells in the tumor microenvironment to an immunostimulatory phenotype. RRx-001 is designed to be used either as a monotherapy or in combination with chemotherapy, radiation therapy or immunotherapy. RRx-001 has Orphan Drug designation from FDA for SCLC, neuroendocrine cancer and glioblastoma, and from EMA for SCLC.

### WP1066: Molculin Biotech

WP1066 is the company's flagship Immune/Transcription Modulator. It has been the subject of over 50 peer-reviewed articles and its activity against p-STAT3 has now been

validated in independent laboratories around the globe. WP1066 and other congeners (molecules similar in structure) in this portfolio have demonstrated in animal models the ability of this new class of agents to increase the natural immune response to tumor activity.

Further product details are provided in the report.....

### Proto oncogene protein c-myc inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Proto oncogene protein c-myc inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players working on Proto oncogene protein c-myc inhibitors

There are approx. 15+ key companies which are developing the Proto oncogene protein c-myc inhibitors. The companies which have their Proto oncogene protein c-myc inhibitors drug candidates in the most advanced stage, i.e. Phase III include, EpicentRx.

#### Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Proto oncogene protein c-myc inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous

Oral

Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

Peptides

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proto oncogene protein c-myc inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-myc inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-myc inhibitors drugs.

Proto oncogene protein c-myc inhibitors Report Insights

Proto oncogene protein c-myc inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Proto oncogene protein c-myc inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Proto oncogene protein c-myc inhibitors drugs?

How many Proto oncogene protein c-myc inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto oncogene protein c-myc inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proto oncogene protein c-myc inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Proto oncogene protein c-myc inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

EpigentRx Inc.

Moleculin Biotech

Peptomyc

Teva Pharmaceutical Industries

Plexxikon

CURACLE

Aptose Biosciences

Kintor Pharmaceutical

Escend Pharmaceuticals

Hillstream BioPharma

## Key Products

RRx-001

WP1066

OMO 103

C41443

PLX 51107

CU 04

APTO-253

GT19077

ES-4000

HSB-510

## Contents

- Introduction
- Executive Summary
- Proto oncogene protein c-myc inhibitors: Overview
  - Structure
  - Mechanism of Action
- Pipeline Therapeutics
  - Comparative Analysis
- Therapeutic Assessment
  - Assessment by Product Type
  - Assessment by Stage and Product Type
  - Assessment by Route of Administration
  - Assessment by Stage and Route of Administration
  - Assessment by Molecule Type
  - Assessment by Stage and Molecule Type
- Proto oncogene protein c-myc inhibitors – DelveInsight's Analytical Perspective
- Late Stage Products (Phase III)
  - Comparative Analysis
- RRx-001: EpicentRx Inc.
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
  - Comparative Analysis
- C41443: Teva Pharmaceutical Industries
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I and I/II)
  - Comparative Analysis
- WP1066: Moleculin Biotech
  - Product Description
  - Research and Development
  - Product Development Activities
- Drug profiles in the detailed report.....
- Pre-clinical and Discovery Stage Products



Comparative Analysis  
ES-4000: Escend Pharmaceuticals  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....  
Inactive Products  
Comparative Analysis  
Proto oncogene protein c-myc inhibitors Key Companies  
Proto oncogene protein c-myc inhibitors Key Products  
Proto oncogene protein c-myc inhibitors- Unmet Needs  
Proto oncogene protein c-myc inhibitors- Market Drivers and Barriers  
Proto oncogene protein c-myc inhibitors- Future Perspectives and Conclusion  
Proto oncogene protein c-myc inhibitors Analyst Views  
Proto oncogene protein c-myc inhibitors Key Companies  
Appendix

## I would like to order

Product name: Proto oncogene protein c-myc inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P1970AC8B816EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P1970AC8B816EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970